Accelerating NSCLC Detection: Strand’s Rapid Deployment of Liquid Biopsy Assays

• Current diagnostic methods for non-small-cell lung cancer are invasive and often delayed. Strand's introduction of a rapid, scalable liquid biopsy assay addresses these challenges head-on.
• Integrated Informatics Workflows: Utilized custom API development to automate primary, secondary, and tertiary bioinformatics processes, improving efficiency and reducing manual intervention.
• Reliable Performance Validation: Achieved robust assay validation, demonstrating the ability to detect mutations with variant allele frequency (VAF) levels of 2-5%, ensuring reliable early detection capabilities.
• Scalable Infrastructure Implementation: Developed a comprehensive informatics infrastructure that supports continuous refinement and large-scale patient cohort analytics, preparing for future enhancements.